×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INCY – incyte corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
08:30 am
incy
Incyte Announces Change to its Board of Directors
Low
Report
Incyte Announces Change to its Board of Directors
12/11
01:28 pm
incy
Microsoft Corporation (MSFT) Presents at Barclays 23rd Annual Global Technology Conference Transcript [Seeking Alpha]
Low
Report
Microsoft Corporation (MSFT) Presents at Barclays 23rd Annual Global Technology Conference Transcript [Seeking Alpha]
12/9
08:11 am
incy
Incyte (NASDAQ:INCY) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
Low
Report
Incyte (NASDAQ:INCY) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
12/9
01:18 am
incy
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? [Yahoo! Finance]
Low
Report
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? [Yahoo! Finance]
12/8
09:37 pm
incy
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]
Low
Report
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]
12/8
04:30 pm
incy
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Low
Report
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
12/8
10:12 am
incy
Incyte (NASDAQ:INCY) was given a new $92.00 price target on by analysts at Morgan Stanley.
Low
Report
Incyte (NASDAQ:INCY) was given a new $92.00 price target on by analysts at Morgan Stanley.
12/8
08:12 am
incy
Incyte (NASDAQ:INCY) was given a new $121.00 price target on by analysts at Mizuho.
Medium
Report
Incyte (NASDAQ:INCY) was given a new $121.00 price target on by analysts at Mizuho.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
04:02 pm
incy
Form 4 INCYTE CORP For: Dec 10 Filed by: Mayes Patrick A
Low
Report
Form 4 INCYTE CORP For: Dec 10 Filed by: Mayes Patrick A
12/12
11:35 am
incy
Form 8-K INCYTE CORP For: Dec 10
Low
Report
Form 8-K INCYTE CORP For: Dec 10
12/11
04:13 pm
incy
Form 144 INCYTE CORP Filed by: Mayes Patrick A
Low
Report
Form 144 INCYTE CORP Filed by: Mayes Patrick A
12/10
05:30 pm
incy
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
Low
Report
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
12/10
04:07 pm
incy
Form 4 INCYTE CORP For: Dec 08 Filed by: Hoppenot Herve
Low
Report
Form 4 INCYTE CORP For: Dec 08 Filed by: Hoppenot Herve
12/10
04:04 pm
incy
Form 144 INCYTE CORP Filed by: Mayes Patrick A
Low
Report
Form 144 INCYTE CORP Filed by: Mayes Patrick A
12/3
04:37 pm
incy
Form 4 INCYTE CORP For: Dec 01 Filed by: Stein Steven H
Low
Report
Form 4 INCYTE CORP For: Dec 01 Filed by: Stein Steven H
12/3
04:36 pm
incy
Form 4 INCYTE CORP For: Dec 01 Filed by: Morrissey Michael James
Low
Report
Form 4 INCYTE CORP For: Dec 01 Filed by: Morrissey Michael James
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/5
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
TOP News Decliners
1/2
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
-9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: